Author

M. Rosenzweig

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Bahreini· 1 shared A. Byford· 1 shared A. Chowdhury· 1 shared A. Dona· 1 shared A. Krishnan· 1 shared A. Loboda· 1 shared A. Palmieri· 1 shared A. V. LEE· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bahreini

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Antibodies to ILT3 abrogate myeloid immunosuppression and enable tumor killing

P. E. Brandish, A. Palmieri, G. Ayanoglu, J. Baker, R. Bueno, A. Byford, M. Caniga, C. Chappell, H. Cherwinski, D. J. Cua, X. Du, L. Fayadat-Dilman, B. E. Hall, H. Issafras, B. Joyce-Shaikh, , J. Zhang-Hoover

This study shows anti-ILT3 antibodies block myeloid immunosuppression and enhance tumor killing in solid tumors.

bioRxiv · Dec 18, 2021 · PreprintCancer Biology

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

Z. Li, Y. Wu, A. Bahreini, N. M. Priedigkeit, K. Ding, C. A. Sartorius, L. Miller, M. Rosenzweig, N. Wagle, J. K. Richer, W. J. Muller, L. Buluwela, S. Ali, Y. Fang, L. Zhu, , S. Oesterreich

This study shows ESR1 mutant breast cancers exhibit basal cytokeratin expression and immune activation, linked to chromatin reprogramming and paracrine signaling.

bioRxiv · Dec 29, 2020 · PreprintCancer Biology

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

D. Viola, A. Dona, E. Caserta, E. Troadec, E. G. Gunes, F. Besi, T. McDonald, L. Ghoda, J. F. Sanchez, J. Khalife, M. Martella, C. Karanes, M. Htut, X. Wang, M. Rosenzweig, , F. Pichiorri

This study shows that daratumumab targets CD38+ NK cells to induce immune activation and anti-myeloma activity despite reducing total NK cell frequency.

bioRxiv · Nov 22, 2019Cancer Biology